ClinicalTrials.gg
RecruitingNCT06430658NEXUS-2Updated Dec 27, 2024

Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer

A Phase 2 interventional study of Tislelizumab (BGB-A317) with chemoradiotherapy in Esophagus Cancer, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-12-27.

Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies testing tislelizumab in Esophageal Neoplasms — 8 open to participants now, 11 under way, 2 of them phase 3. tislelizumab · Esophageal Neoplasms.

Planned enrollment
5th of 13
90 · median 40
Started
2024
with 1 other
Phase 2
11 of 13
7 open now
Primary completion
2026-12
later than 8 of 10 live
Registered
7th of 13
by date
Lead sponsor
1 of 13
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Among the 13 studies testing tislelizumab in Esophageal Neoplasms, this one is the 5th largest by planned enrollment, is one of 2 that started in 2024, is one of 11 in phase 2, reaches primary completion later than 8 of the 10 other live ones, and was the 7th registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

8 of the 13 studies testing tislelizumab in Esophageal Neoplasms are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About tislelizumab

tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing tislelizumab in Esophageal Neoplasms, or all of them as a file.
02

Study summary

Patients diagnosed with locally advanced esophageal squamous cell carcinoma (ESCC) that is deemed unresectable face a bleak prognosis. Recent phase 1/2 studies have demonstrated the efficacy and safety of augmenting neoadjuvant concurrent chemoradiotherapy with immunotherapy in treating resectable ESCC. The present study is a prospective, 3-arm, randomized trial that seeks to evaluate the efficacy of diverse conversion therapy modalities in patients with unresectable ESCC. The study objectives include R0 resection rate, treatment-related adverse events, morbidity and mortality, 1-year progression-free survival (PFS), and 1-year overall survival (OS) rates.

Tislelizumab is a humanized IgG4 monoclonal antibody with high affinity/specificity for programmed cell death protein 1 (PD-1). Tislelizumab was specifically engineered to minimize binding to FcɤR on macrophages, thereby abrogating antibody-dependent phagocytosis, a potential mechanism of T-cell clearance and resistance to anti-PD-1 therapy.

This trial will provide valuable insights into the effectiveness of the three conversion therapy modalities and help to inform clinical decision-making for patients with unresectable locally advanced ESCC.

03

Conditions studied

  • Esophagus Cancer

Keywords

  • Esophagus Cancer
  • Chemoradiotherapy
  • conversion surgery
  • immunotherapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed sorely ESCC without other histology subtypes.
  2. Thoracic esophageal cancer.
  3. No prior anti-cancer treatment, including but not limited to surgery, radiotherapy, chemotherapy, targeted therapy, or immunotherapy.
  4. Borderline unresectable locally advanced ESCC deemed by investigators as suspicious of but not confirmed T4b according to the American Joint Committee on Cancer (AJCC) 8th edition staging classification or extracapsular lymph node involvement (ELNI).
  5. The Performance Scale (KPS) ≥70.
  6. Normal primary organ functions, including but not limited to (Hb) ≥ 100g/L; white blood cell (WBC) ≥ 3.5×10*9/L; (NEUT) ≥ 1.5×10*9/L; (PLT) ≥ 100×10*9/L; (ALT) and aspartate aminotransferase (AST) ≤ 1.5×UNL; total (TBIL) ≤ 1.5×UNL; creatinine ≤ 1.5UNL; blood urea nitrogen (BUN) ≤ 1.0×UNL.

Exclusion criteria

Exclusion Criteria:

  1. Synchronous and metachronous primary in but not limited to the upper aerodigestive tract, except for cured basal cell carcinoma of the skin and carcinoma in situ of the cervix.
  2. Patients have undergone any type of anti-cancer treatment.
  3. Baseline clinical stage M1 per AJCC 8th edition of staging classification, including supraclavicular lymph node .
  4. Investigators assessed major vessel involvement with high-risk hemorrhage.
  5. A higher probability of esophageal perforation during conversion therapy.
  6. Active infectious diseases, including but not limited to tuberculosis, virus, or virus.
  7. Allergic to anti-cancer agents, including but not limited to or chemotherapy agents.
  8. Given cardiopulmonary dysfunction, patients can not tolerate conversion therapy or surgery.
  9. Pregnant or lactating women and women of who lacked effective .
  10. Non-compliance with the inclusion criteria judged by investigators.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    ChemoRT+Immuno

    Surgery was evaluated after chemoradiotherapy (40-41.4Gy/1.8-2Gy/20-23 fractions) followed by two cycles of chemotherapy and immunotherapy.For inoperable patients, immunotherapy was used as maintenance therapy

    Combination Product: Tislelizumab (BGB-A317) with chemoradiotherapy

  • Experimental
    Immuno+ChemoRT

    Surgery was evaluated after two cycles of chemotherapy and immunotherapy followed by chemoradiotherapy(40-41.4Gy/1.8-2Gy/20-23 fractions).For inoperable patients, immunotherapy was used as maintenance therapy

    Combination Product: Tislelizumab (BGB-A317) with chemoradiotherapy

  • Active comparator
    ChemoRT

    Surgery was evaluated after concurrent definitive chemoradiotherapy (50-50.4Gy/1.8-2Gy/25-28fractions) .For inoperable patients, immunotherapy was used as maintenance therapy

    Combination Product: Tislelizumab (BGB-A317) with chemoradiotherapy

Interventions

  • Combination productTislelizumab (BGB-A317) with chemoradiotherapy

    Drug page: TislelizumabStudies of TislelizumabTislelizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Different sequences and methods of treatment to convert surgery

06

What researchers measure

Primary outcomes

  1. R0 resection rate

    Minimal distance tumor/circumferential resection margin (CRM) \> 1 mm.

    Time frame: 4 months

Secondary outcomes

  1. 1-year OS rate

    Defined as the proportion of patients still alive within one year from treatment initiation.

    Time frame: 1 year after all treatment

  2. 1-year PFS

    Defined as the proportion of patients without disease progression or death within one year from treatment initiation.

    Time frame: 1 year after all treatment

  3. Positive rate of circulating tumor DNA (ctDNA) in minimal residual disease (MRD) before and after neoadjuvant treatment and its correlation with the pathological response and disease progression during surveilance

    To investigate whether ctDNA variation can be used for MRD predicting incidence of pathological incidence and monitoring tumor progression after surgery

    Time frame: 6 month

  4. Incidence of Treatment-Emergent Adverse Events

    Adverse event during chemoRT or immunotherapy

    Time frame: 4 month

  5. Pathological response rate

    Time frame: 4 month

  6. Postoperative complications

    Time frame: 4 month

07

Study locations

1 of 1 sites recruiting
  • Department of Radiation Oncology, Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)
    Beijing, 100021, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Dec 2026, 32 months after the start.

Of 174 non-industry phase 2 interventional studies under Esophageal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 85. This study's planned 32 months is below that.

Counting every sponsor, half of 198 studies reached it within 52 months; a quarter within 33 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2024
First posted
May 28, 2024
StartActual
Apr 1, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Dec 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06430658
Responsible party
YIN LI (Principal Investigator, Cancer Institute and Hospital, Chinese Academy of Medical Sciences) — Principal investigator
First posted
May 28, 2024
Start date
Apr 1, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Dec 27, 2024

Study contacts

Xin Wang, Doctor
Contact
beryl_wx2000@163.com
13311583220
Ziyu Zheng, B.M
Contact
zy_zhengw@163.com
13552252161

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tislelizumab

Start the discussion